Generic Pharma, generic manufacturer India, Generics Supplier, Generic Exporter, Pharmaceuticals Generic Medicines Manufacturer Hydroxyurea, Hydroxyurea manufacturer India, gynace product, anti-biotic skin products, anti cold preparation, anti bacterials, gynec, nutritional product, Hydroxyurea anti ulcer product, Hydroxyurea, pharmaceutical generic, pharmaceutical drug, medical, pharma healthcare, pharma patents, contract manufacturing Hydroxyurea pharma, generic pharma, pharma pharmaceutical products, pharmaceutical formulations, generic medicine, anti-biotics, anti-fungal, skin care Manufacturer, gynaec, nutritional, anti-cold, expectorant Pharmaceutical gmp formulations manufacturer, Hydroxyurea pharmaceutical medicine exporter from India, pharma Hydroxyurea medicine, api, generic medicine Hydroxyurea, herbal products, health care products, tablets, capsules, syrup & protein Hydroxyurea powder, nutraceuticals, gynec products, ortho products in India, oncology products, gastroenterology products, orthopaedic products, gynecology, who gmp, cGMP, US FDA, WHO, UKMHRA Approved Hydroxyurea Capsules, drug imprint information, side effects for the patient, Tharolax (Hydroxyurea Capsules), drug imprint information, side effects for the patient, Tharolax Hydroxyurea Capsules possible side effects drug images pictures what is precautions images pictures detailed patient information caregiver patients medications drugs generic, Tharolax (Hydroxyurea Capsules) Patient Information: Side Effects and Drug Images, Tharolax Hydroxyurea Capsules drug description chemical structure black box warning medications drugs generic fda approved patient labeling reviews professionals clinicians clinical, Tharolax (Hydroxyurea Capsules) Drug Information: Description, User Reviews, Drug Side Effects, Interactions - Prescribing Information, prescription medication Tharolax (Hydroxyurea Capsules), drug uses, dosage, side effects, drug interactions, warnings, reviews and patient labelling, Blood and bone marrow cancers, Tharolax 500mg capsules, used in the treatment of Blood and bone marrow cancers, YDROXYUREA - ORAL (Tharolax) side effects, medical uses, and drug interactions, HYDROXYUREA - ORAL (Tharolax) side effects, medical uses, and drug interactions, HYDROXYUREA - ORAL (Tharolax), includes side effects, drug interactions, recommended dosages, and storage information. Read more about the prescription drug HYDROXYUREA – ORAL,

Home » Taj Pharma » Manufacturing

Manufacturing

Manufacturing and Facilities : The manufacturing facilities are based in Valsad (Gujarat) and Raigad (Raigarh, Maharashtra) and operated by Taj Pharmaceuticals Ltd and its subsidiaries.

In our quest to be the leading manufacturer in the pharmaceutical industry and a CRAMS player of global standing; we aspire to meet and excel the highest industry standards. To this end, on the manufacturing front, we have designed and engineered our production facilities to the most rigorous benchmarks.

manufacturing unit

We have a modern fdafacility for the production of sterile powder formulations, non-sterile oral formulations and active pharmaceutical ingredients.

pharma manufacturing

Some other features of our facility:

  • Modern QA, QC, Microbiological and PD Lab supported with high-tech equipment.
  • Fully automated with electronically controlled operating system as per Good Automated Manufacturing Practice    guidelines (GMP).
  • Sophisticated Effluent Treatment Plant (ETP) with a capacity of 100,000 liters per day.
  • Conforms to international environmental, health & safety regulations

Our facility consistently meets and exceeds our own stringent quality assurance standards, administered by an Internal Quality Assurance team reporting directly to the Managing Director, as well as those imposed by regulatory bodies. IQ /OQ / PQ validations have been completed on all equipment to which these apply.

In addition, we are a registered drug manufacturing facility with an impressive inspection record. All our manufacturing sites are WHO-GMP approved.

Our expertise APIs (CTD & formulation dossiers) will help us further enhance our own product range as well as the size and diversity of our toll / contract manufacturing business segment.

Modern methods like aqueous coating, tablet packing in combi-packs etc., are implemented in the manufacturing process.

The Sarigam plant is the Only plant in the world producing all the effective ranges of Anti-tuberculosis formulations namely Ethambutol Hydrochloride (B.P.), Rifampicin (B.P.), Isoniazid (B.P.), Pyrazinamide (B.P.), Rifampicin-Isoniazid (B.P.), Rifampicin-Isoniazid-Pyrazinamide (B.P.), Ethionamide (B.P.) and Prothionamide (B.P.) - all in Tablet form. Production of bulk actives such as Ethambutol, Rifampicin and Pyrazinamide are also undertaken at Valsad, Gujrat (India).

R & D activity is a continuous on-going process and the R & D Division at Sarigam has been duly approved by the Department of Scientific and Industrial Research, (DSIR), Government of India.

The Raigad Plant, which is involved in Fermentation activity has been suitably up-graded and manufactures products like - Lovastatin, Simvastatin, DMCTC, Gentamycin, Sisomycin, etc., The Plant also exclusively manufactures a veterinary product for a foreign multinational - in fact is the only manufacturer of this product in the world.

For More information visit www.tajpharma.com

Important Safety Information

Treatment of patients with THAROLAX may be complicated by severe, sometimes lifethreatening, adverse effects. THAROLAX should be administered under the supervision of a physician experienced in the use of this medication for the treatment of sickle cell anemia.

Hydroxyurea is mutagenic and clastogenic, and causes cellular transformation to a tumorigenic phenotype. Hydroxyurea is thus unequivocally genotoxic and a presumed transspecies carcinogen which implies a carcinogenic risk to humans. In patients receiving long-term hydroxyurea for myeloproliferative disorders, such as polycythemia vera and thrombocythemia, secondary leukaemia’s have been reported. It is unknown whether this leukemogenic effect is secondary to hydroxyurea or is associated with the patient's underlying disease. The physician and patient must very carefully consider the potential benefits of THAROLAX relative to the undefined risk of developing secondary malignancies. Tharolax is used to treat chronic myeloid leukaemia or cervical cancer.

Your medical team will discuss with you the options for treating your cancer. They will take into account factors such as the type of cancer, where it is, which stage it is at and whether you have had treatment before. The results of blood tests and other investigations will also be considered. How well you feel and how you are likely to cope with treatment is also important.

Your cancer treatment will usually consist of a treatment session with Tharolax followed by a break of a number of days before the next treatment session with Tharolax. This cycle may be repeated many times as part of your cancer treatment. Tharolax works by damaging cancer cells in the body. Tharolax also affects healthy cells and treatment with Tharolax may damage your immune system. Your medical team may arrange for you to have some blood tests to check how well your immune system is working. Do not share your medicine with other people. It may not be suitable for them and may harm them. The pharmacy label on your medicine tells you how much medicine you should take. It also tells you how often you should take your medicine. This is the dose that you and your prescriber have agreed you should take. You should not change the dose of your medicine unless you are told to do so by your prescriber. If you feel that the medicine is making you unwell or you do not think it is working, then talk to your prescriber.

Patient Information

Full Prescribing Information